Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors

Open access
Lusher, Jeanne M., Arkin, Steven, Abildgaard, Charles F., Schwartz, Richard S. · 1993 · New England Journal of Medicine

Abstract

BACKGROUND: Although methods of viral attenuation in plasma-derived clotting-factor concentrates have improved, there is still a possibility that such concentrates may transmit certain blood-borne viruses. For this reason, the use of recombinant DNA-derived factor VIII (which is virus-free) to treat hemophilia A has generated considerable interest. METHODS: We conducted a multicenter trial in previously untreated children with hemophilia A. They received recombinant factor VIII for all treatment or for prophylaxis and were evaluated at their respective clinics at intervals of no more than three months. RESULTS: Between January 1, 1989, and July 1, 1992, 95 patients who could be evaluated received recombinant factor VIII. By September 1, 1992, they had received the concentrate exclusively for 2.4 months to 3.5 years (median, 1.5 years). All responded well, with no treatment failures. A total of 3315 infusions were administered; there were three reports of minor adverse reactions. Inhibitor antibodies to factor VIII developed in 16 of 81 patients tested for them, after a median of nine days of exposure to factor VIII treatment. Inhibitor titers were or became low in 9 of the 16 patients despite continued episodic treatment with the concentrate. Inhibitors disappeared completely in 4 patients and remained at a low level (< 10 Bethesda units) in 5 patients receiving episodic treatment. CONCLUSIONS: Transient or low levels of inhibitor, as observed in this study, may represent part of the natural history of hemophilia in infants. In view of the transient nature and lower concentration of the inhibitors detected and the generally satisfactory response to treatment, the benefits of recombinant factor VIII for the treatment of hemophilia seem to outweigh the risks.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm199302183280701

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 29 references

Research works printed but not linked: 10

  1. 1991, Blood, 78, 1409
  2. Chan SY, 1991, Semin Hematol, 28, 10
  3. Klein U, 1991, Semin Hematol, 28, 17
  4. Kasper CK, 1975, Thromb Diath Haemorrh, 34, 869
  5. Hoyer LW, 1984, Prog Clin Biol Res, 150, 73
  6. Hoyer LW, 1991, Blood Coagul Fibrinolysis, 2, 11
  7. Lusher JM, 1991, Blood Coagul Fibrinolysis, 2, 1
  8. Gill FM, 1984, Prog Clin Biol Res, 150, 19
  9. 1990, Semin Hematol, 27, 1
  10. Fournel MA, 1991, Semin Hematol, 28, 22

Cited by

See all 476

Metadata

Authors
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S.
Affiliations
  • Children's Hospital of Michigan (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of California, Davis (US)
Venue
New England Journal of Medicine
Published
1993-02-18
Volume
328
Issue
7
Pages
453-459
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2337290468
Cited by
476
References
29
Citations by year
2026: 2 · 2025: 6 · 2024: 3 · 2023: 4 · 2022: 7 · 2021: 8 · 2020: 10 · 2019: 10 · 2018: 9 · 2017: 13 · 2016: 14 · 2015: 19 · 2014: 12 · 2013: 15 · 2012: 13
FWCI
15.91
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
  • Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
Keywords
recombinant factor VIII, hemophilia A, treatment-naive patients, factor VIII inhibitors, prophylaxis, episodic treatment, children, treatment safety, treatment efficacy, blood-borne virus transmission
MeSH terms
Antibodies, Antibody Formation, Factor VIII, Hemophilia A, Humans, Infant, Recombinant Proteins, Time Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. https://app.cochat.ai/papers/10.1056/nejm199302183280701
The paper
Lusher, J. M., Arkin, S., Abildgaard, C. F., & Schwartz, R. S. (1993). Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. New England Journal of Medicine. https://doi.org/10.1056/nejm199302183280701

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.